The AACR meeting was full of promising data on the vaccine against cervical cancer, a lung cancer drug and the next ...

Revolution Medicines' zoldonrasib shows 61% response rate in lung cancer patients with KRAS G12D mutations in Phase 1 trial, ...

Preclinical data demonstrates synergy of QTX3544 with EGFR inhibitors, broadly enhancing anti-tumor activity - - Data supports ongoing Phase 1 clinical trial for QTX3544 as monotherapy and in ...

Revolution Medicines, Inc. (NASDAQ:RVMD) on Sunday announced new clinical data for zoldonrasib (RMC-9805), a RAS(ON) ...

“This trial is the first time we’ve ever seen this kind of benefit in treating non-small cell lung cancers caused by KRAS-G12D,” Dr. Arbour says. “What we saw in these patients is dramatically ...

A novel combination therapy offers better outcomes for patients with KRAS G12C metastatic colorectal cancer that have stopped ...

Researchers from The University of Texas MD Anderson Cancer Center will present promising results from clinical trials in ...

Pancreatic cancer is a leading cause of cancer-related death, with a five-year survival rate of 13%. The high mortality is ...

A novel combination therapy offers better outcomes for patients with KRAS G12C metastatic colorectal cancer that have stopped responding to chemotherapy, according to a Phase 3 clinical trial by ...

Verastem will launch a U.S. phase 1/2a trial of oral KRAS G12D inhibitor VS-7375 after FDA IND clearance, with data to be ...

Cogent Biosciences (COGT) announced preclinical data from four pipeline programs during poster sessions at the American Association for Cancer ...